Global Long-Acting HIV PrEP Market Growth (Status and Outlook) 2026-2032
The global Long-Acting HIV PrEP market size is predicted to grow from US$ 1177 million in 2025 to US$ 12826 million in 2032; it is expected to grow at a CAGR of 38.9% from 2026 to 2032.
Long-Acting HIV PrEP refers to long-duration antiretroviral pre-exposure prophylaxis delivered through scheduled injectable formulations to reduce the risk of sexually acquired HIV-1 infection in HIV-negative individuals. This study focuses on commercially established long-acting injectable PrEP based on cabotegravir and lenacapavir, covering intramuscular and subcutaneous administration, dosing schedules ranging from every two months to every six months, and the corresponding integrase strand transfer inhibitor and HIV-1 capsid inhibitor mechanisms. These products are administered through professional healthcare settings and require confirmation of HIV-negative status before initiation and appropriate testing during continued use. The principal downstream settings include hospitals and HIV specialty clinics, sexual health clinics, community health centers and public-health PrEP programs. Compared with daily oral prevention, the defining commercial attribute of Long-Acting HIV PrEP is the extension of effective drug exposure across substantially longer dosing intervals, creating a differentiated prevention option for users seeking lower dosing frequency and for healthcare systems aiming to improve persistence with PrEP programs.
Key Findings
The average gross profit margin of this product is 90%
Commercial Long-Acting HIV PrEP now spans two distinct injectable mechanisms
Current dosing intervals range from every two to every six months
Cabotegravir holds an earlier commercial position in long-acting injectable PrEP
Lenacapavir extends injectable HIV prevention to a twice-yearly dosing schedule
Scheduled HIV testing remains integral to long-acting injectable PrEP delivery
Market Trends
The Long-Acting HIV PrEP market is transitioning from a single long-acting injectable concept toward a differentiated platform defined by dosing duration, administration route and mechanism of action. Cabotegravir established the every-two-month intramuscular model, while lenacapavir has extended the interval to twice-yearly subcutaneous administration, materially changing the competitive benchmark for dosing convenience. The longer-term direction of the market is therefore shifting from simply replacing daily tablets toward reducing the number of prevention-related dosing events while preserving reliable clinical follow-up. At the same time, product innovation is increasingly being linked with simplified HIV testing, differentiated service delivery and integration into broader sexual-health and public-health programs. WHO recommendations covering both long-acting cabotegravir and lenacapavir reinforce the development of a multi-option PrEP environment in which long-acting injectables are positioned alongside other prevention choices rather than as a uniform replacement for all existing PrEP approaches.
Market Dynamics
Drivers
Demand for Long-Acting HIV PrEP is primarily supported by the persistent challenge of maintaining adherence to frequently dosed prevention regimens and by growing emphasis on expanding user choice within HIV prevention. Injectable products reduce the number of medication-taking events required over a year and may be particularly relevant for users who experience difficulties with daily pill adherence, privacy concerns or stigma associated with storing and taking oral medication. Regulatory approvals and inclusion of long-acting injectable options in international HIV prevention recommendations have also strengthened the clinical foundation for broader implementation. In parallel, governments and public-health organizations increasingly view diversified PrEP options as a means of improving effective prevention coverage rather than relying on a single delivery model.
Restraints
The main restraints arise from the more structured service requirements associated with injectable PrEP. Unlike self-administered daily oral medication, current long-acting injections generally require healthcare-provider administration, scheduled return visits and HIV testing before initiation and during continued use. Missed or significantly delayed dosing may complicate preventive management, while use in individuals with undiagnosed HIV infection can create drug-resistance concerns. These operational requirements increase dependence on clinic capacity, patient tracking, reimbursement and reliable appointment systems. Consequently, the commercial advantage of lower dosing frequency does not automatically translate into easier healthcare delivery, particularly in markets where HIV testing infrastructure, trained providers or financing for preventive services remains limited.
Opportunities
The principal opportunity lies in expanding PrEP participation among populations that have not been effectively retained by conventional prevention delivery models. Longer dosing intervals create potential for more differentiated service models linking HIV specialty care, sexual-health clinics, community health centers and public-health programs. Simplified testing approaches may further support decentralization of long-acting PrEP services and reduce operational barriers to initiation and continuation. The twice-yearly dosing model also provides a new reference point for future product development, potentially shifting competitive differentiation toward duration of protection, ease of administration and service efficiency. Markets with substantial unmet HIV prevention needs represent an important long-term opportunity, although realization of this potential will depend heavily on national guidelines, procurement mechanisms, reimbursement and access programs.
Challenges
Long-Acting HIV PrEP creates new implementation challenges alongside its adherence advantages. Healthcare systems must maintain accurate HIV-negative confirmation, injection scheduling and follow-up over extended intervals, while providers must manage individuals who miss injections or discontinue treatment. The prolonged pharmacologic activity that supports long dosing intervals also makes resistance management and testing strategy particularly important if HIV infection occurs during periods of declining drug concentration. At the market level, differences in regulatory approval, reimbursement, public-health funding and provider readiness can produce substantial variation in adoption between countries. Manufacturers therefore face the dual task of demonstrating strong prevention performance while building scalable delivery systems that translate clinical efficacy into consistent real-world uptake.
Industry Chain Analysis
The Long-Acting HIV PrEP industry chain begins with antiretroviral active pharmaceutical ingredients, pharmaceutical excipients, formulation materials and sterile injectable manufacturing inputs. The middle of the chain encompasses long-acting formulation development, sterile production and fill-finish, quality control, clinical development, regulatory registration, packaging and product supply. Compared with conventional solid-dose medicines, the technical value of the product is concentrated not only in the active ingredient but also in achieving controlled and persistent drug exposure over extended periods through specialized injectable formulations. This makes formulation technology, clinical evidence, intellectual property and regulatory capability major components of product value.
Downstream value is realized through hospitals, HIV specialty clinics, sexual-health services, community healthcare facilities and public-health PrEP programs. Because the products require HIV testing and professionally managed dosing schedules, manufacturers depend more heavily on healthcare-delivery infrastructure than suppliers of self-administered preventive medicines. Commercial performance is therefore influenced not only by pharmaceutical production costs but also by reimbursement, procurement, clinical workflow integration, patient identification and long-term retention. As dosing frequency decreases, the industry chain is likely to place greater emphasis on reliable patient recall systems and coordinated prevention services rather than prescription volume alone.
Segment Insights
The current Long-Acting HIV PrEP market is structured around two differentiated pharmacological segments. Cabotegravir Long-Acting PrEP is an integrase strand transfer inhibitor delivered through intramuscular injection, with maintenance dosing every two months after initiation. Its earlier regulatory commercialization gives it a comparatively established position in injectable PrEP service models. Lenacapavir Long-Acting PrEP represents the newer HIV-1 capsid inhibitor segment and uses subcutaneous administration with maintenance dosing every six months, introducing a substantially longer injection interval and a differentiated mechanism of action.
From a product-structure perspective, competition is therefore moving beyond basic injectable versus oral differentiation. Intramuscular and subcutaneous administration, two-month and six-month intervals, and INSTI versus capsid-inhibitor mechanisms form distinct commercial positioning dimensions. Cabotegravir benefits from an earlier market-entry profile and accumulated implementation experience, while lenacapavir raises the benchmark for dosing duration. The relative development of these segments will increasingly depend on patient preference, provider workflow, reimbursement, persistence with scheduled visits and the ability of prevention programs to integrate each dosing model efficiently.
Downstream Market Opportunities
Downstream demand for Long-Acting HIV PrEP is concentrated in professionally managed HIV prevention settings rather than conventional retail drug channels. HIV specialty clinics and sexual-health clinics are natural early-adoption environments because testing, risk assessment, counseling and injection administration can be integrated within established workflows. Community health centers and public-health PrEP programs represent a broader expansion opportunity as testing and preventive services become more decentralized. The commercial opportunity is particularly significant where providers can identify individuals with substantial HIV exposure risk but low persistence with frequently dosed prevention. Future market expansion will therefore depend on converting long dosing intervals into practical improvements in retention, convenience and continuity of prevention services rather than relying solely on pharmacological differentiation.
Regional Insights
North America currently represents the most mature commercialization environment within the Long-Acting HIV PrEP market, reflecting earlier regulatory introduction of cabotegravir and subsequent launch of twice-yearly lenacapavir in the United States. Europe has also developed a broader long-acting PrEP portfolio following regulatory authorization of cabotegravir and later lenacapavir, providing a second major regulated market for competing long-duration injection strategies. These markets benefit from comparatively established HIV testing networks, specialty care infrastructure and reimbursement mechanisms, although access can still vary by healthcare system.
In other regions, market development is more closely tied to national HIV prevention policies, public procurement, donor-supported programs, regulatory timelines and healthcare-delivery capacity. WHO recommendations for both cabotegravir and lenacapavir create an important policy foundation for broader adoption, particularly in markets with high unmet prevention needs. However, commercial maturity is likely to remain uneven because clinical availability does not automatically translate into funded and scalable access. For manufacturers, regional expansion will increasingly require differentiated pricing, public-health partnerships and service-delivery models adapted to local testing and follow-up capacity.
Competitive Landscape Analysis
The confirmed commercial landscape of Long-Acting HIV PrEP is highly concentrated around ViiV Healthcare and Gilead Sciences, but their competitive positioning is differentiated rather than directly homogeneous. ViiV Healthcare established the earlier long-acting injectable PrEP model through cabotegravir, building its position around an intramuscular regimen with maintenance injections every two months. Gilead Sciences subsequently entered the market with lenacapavir and differentiated its offering through a novel HIV-1 capsid mechanism and twice-yearly subcutaneous dosing. As a result, competition is increasingly centered on dosing interval, route of administration, implementation convenience, clinical confidence and access rather than price alone. ViiV's earlier commercialization supports accumulated provider familiarity, whereas Gilead's six-month dosing interval creates a strong product-level differentiation point. Future competitive outcomes will depend on how effectively each company converts these pharmacological and dosing characteristics into sustained patient uptake, reimbursement coverage and integration into national and community-based HIV prevention programs.
Report Scope
LPI (LP Information)' newest research report, the “Long-Acting HIV PrEP Industry Forecast” looks at past sales and reviews total world Long-Acting HIV PrEP sales in 2025, providing a comprehensive analysis by region and market sector of projected Long-Acting HIV PrEP sales for 2026 through 2032. With Long-Acting HIV PrEP sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-Acting HIV PrEP industry.
This Insight Report provides a comprehensive analysis of the global Long-Acting HIV PrEP landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Long-Acting HIV PrEP portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-Acting HIV PrEP market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-Acting HIV PrEP and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-Acting HIV PrEP.
This report presents a comprehensive overview, market shares, and growth opportunities of Long-Acting HIV PrEP market by product type, application, key players and key regions and countries.
Market Segmentation
Long-Acting HIV PrEP refers to long-duration antiretroviral pre-exposure prophylaxis delivered through scheduled injectable formulations to reduce the risk of sexually acquired HIV-1 infection in HIV-negative individuals. This study focuses on commercially established long-acting injectable PrEP based on cabotegravir and lenacapavir, covering intramuscular and subcutaneous administration, dosing schedules ranging from every two months to every six months, and the corresponding integrase strand transfer inhibitor and HIV-1 capsid inhibitor mechanisms. These products are administered through professional healthcare settings and require confirmation of HIV-negative status before initiation and appropriate testing during continued use. The principal downstream settings include hospitals and HIV specialty clinics, sexual health clinics, community health centers and public-health PrEP programs. Compared with daily oral prevention, the defining commercial attribute of Long-Acting HIV PrEP is the extension of effective drug exposure across substantially longer dosing intervals, creating a differentiated prevention option for users seeking lower dosing frequency and for healthcare systems aiming to improve persistence with PrEP programs.
Key Findings
The average gross profit margin of this product is 90%
Commercial Long-Acting HIV PrEP now spans two distinct injectable mechanisms
Current dosing intervals range from every two to every six months
Cabotegravir holds an earlier commercial position in long-acting injectable PrEP
Lenacapavir extends injectable HIV prevention to a twice-yearly dosing schedule
Scheduled HIV testing remains integral to long-acting injectable PrEP delivery
Market Trends
The Long-Acting HIV PrEP market is transitioning from a single long-acting injectable concept toward a differentiated platform defined by dosing duration, administration route and mechanism of action. Cabotegravir established the every-two-month intramuscular model, while lenacapavir has extended the interval to twice-yearly subcutaneous administration, materially changing the competitive benchmark for dosing convenience. The longer-term direction of the market is therefore shifting from simply replacing daily tablets toward reducing the number of prevention-related dosing events while preserving reliable clinical follow-up. At the same time, product innovation is increasingly being linked with simplified HIV testing, differentiated service delivery and integration into broader sexual-health and public-health programs. WHO recommendations covering both long-acting cabotegravir and lenacapavir reinforce the development of a multi-option PrEP environment in which long-acting injectables are positioned alongside other prevention choices rather than as a uniform replacement for all existing PrEP approaches.
Market Dynamics
Drivers
Demand for Long-Acting HIV PrEP is primarily supported by the persistent challenge of maintaining adherence to frequently dosed prevention regimens and by growing emphasis on expanding user choice within HIV prevention. Injectable products reduce the number of medication-taking events required over a year and may be particularly relevant for users who experience difficulties with daily pill adherence, privacy concerns or stigma associated with storing and taking oral medication. Regulatory approvals and inclusion of long-acting injectable options in international HIV prevention recommendations have also strengthened the clinical foundation for broader implementation. In parallel, governments and public-health organizations increasingly view diversified PrEP options as a means of improving effective prevention coverage rather than relying on a single delivery model.
Restraints
The main restraints arise from the more structured service requirements associated with injectable PrEP. Unlike self-administered daily oral medication, current long-acting injections generally require healthcare-provider administration, scheduled return visits and HIV testing before initiation and during continued use. Missed or significantly delayed dosing may complicate preventive management, while use in individuals with undiagnosed HIV infection can create drug-resistance concerns. These operational requirements increase dependence on clinic capacity, patient tracking, reimbursement and reliable appointment systems. Consequently, the commercial advantage of lower dosing frequency does not automatically translate into easier healthcare delivery, particularly in markets where HIV testing infrastructure, trained providers or financing for preventive services remains limited.
Opportunities
The principal opportunity lies in expanding PrEP participation among populations that have not been effectively retained by conventional prevention delivery models. Longer dosing intervals create potential for more differentiated service models linking HIV specialty care, sexual-health clinics, community health centers and public-health programs. Simplified testing approaches may further support decentralization of long-acting PrEP services and reduce operational barriers to initiation and continuation. The twice-yearly dosing model also provides a new reference point for future product development, potentially shifting competitive differentiation toward duration of protection, ease of administration and service efficiency. Markets with substantial unmet HIV prevention needs represent an important long-term opportunity, although realization of this potential will depend heavily on national guidelines, procurement mechanisms, reimbursement and access programs.
Challenges
Long-Acting HIV PrEP creates new implementation challenges alongside its adherence advantages. Healthcare systems must maintain accurate HIV-negative confirmation, injection scheduling and follow-up over extended intervals, while providers must manage individuals who miss injections or discontinue treatment. The prolonged pharmacologic activity that supports long dosing intervals also makes resistance management and testing strategy particularly important if HIV infection occurs during periods of declining drug concentration. At the market level, differences in regulatory approval, reimbursement, public-health funding and provider readiness can produce substantial variation in adoption between countries. Manufacturers therefore face the dual task of demonstrating strong prevention performance while building scalable delivery systems that translate clinical efficacy into consistent real-world uptake.
Industry Chain Analysis
The Long-Acting HIV PrEP industry chain begins with antiretroviral active pharmaceutical ingredients, pharmaceutical excipients, formulation materials and sterile injectable manufacturing inputs. The middle of the chain encompasses long-acting formulation development, sterile production and fill-finish, quality control, clinical development, regulatory registration, packaging and product supply. Compared with conventional solid-dose medicines, the technical value of the product is concentrated not only in the active ingredient but also in achieving controlled and persistent drug exposure over extended periods through specialized injectable formulations. This makes formulation technology, clinical evidence, intellectual property and regulatory capability major components of product value.
Downstream value is realized through hospitals, HIV specialty clinics, sexual-health services, community healthcare facilities and public-health PrEP programs. Because the products require HIV testing and professionally managed dosing schedules, manufacturers depend more heavily on healthcare-delivery infrastructure than suppliers of self-administered preventive medicines. Commercial performance is therefore influenced not only by pharmaceutical production costs but also by reimbursement, procurement, clinical workflow integration, patient identification and long-term retention. As dosing frequency decreases, the industry chain is likely to place greater emphasis on reliable patient recall systems and coordinated prevention services rather than prescription volume alone.
Segment Insights
The current Long-Acting HIV PrEP market is structured around two differentiated pharmacological segments. Cabotegravir Long-Acting PrEP is an integrase strand transfer inhibitor delivered through intramuscular injection, with maintenance dosing every two months after initiation. Its earlier regulatory commercialization gives it a comparatively established position in injectable PrEP service models. Lenacapavir Long-Acting PrEP represents the newer HIV-1 capsid inhibitor segment and uses subcutaneous administration with maintenance dosing every six months, introducing a substantially longer injection interval and a differentiated mechanism of action.
From a product-structure perspective, competition is therefore moving beyond basic injectable versus oral differentiation. Intramuscular and subcutaneous administration, two-month and six-month intervals, and INSTI versus capsid-inhibitor mechanisms form distinct commercial positioning dimensions. Cabotegravir benefits from an earlier market-entry profile and accumulated implementation experience, while lenacapavir raises the benchmark for dosing duration. The relative development of these segments will increasingly depend on patient preference, provider workflow, reimbursement, persistence with scheduled visits and the ability of prevention programs to integrate each dosing model efficiently.
Downstream Market Opportunities
Downstream demand for Long-Acting HIV PrEP is concentrated in professionally managed HIV prevention settings rather than conventional retail drug channels. HIV specialty clinics and sexual-health clinics are natural early-adoption environments because testing, risk assessment, counseling and injection administration can be integrated within established workflows. Community health centers and public-health PrEP programs represent a broader expansion opportunity as testing and preventive services become more decentralized. The commercial opportunity is particularly significant where providers can identify individuals with substantial HIV exposure risk but low persistence with frequently dosed prevention. Future market expansion will therefore depend on converting long dosing intervals into practical improvements in retention, convenience and continuity of prevention services rather than relying solely on pharmacological differentiation.
Regional Insights
North America currently represents the most mature commercialization environment within the Long-Acting HIV PrEP market, reflecting earlier regulatory introduction of cabotegravir and subsequent launch of twice-yearly lenacapavir in the United States. Europe has also developed a broader long-acting PrEP portfolio following regulatory authorization of cabotegravir and later lenacapavir, providing a second major regulated market for competing long-duration injection strategies. These markets benefit from comparatively established HIV testing networks, specialty care infrastructure and reimbursement mechanisms, although access can still vary by healthcare system.
In other regions, market development is more closely tied to national HIV prevention policies, public procurement, donor-supported programs, regulatory timelines and healthcare-delivery capacity. WHO recommendations for both cabotegravir and lenacapavir create an important policy foundation for broader adoption, particularly in markets with high unmet prevention needs. However, commercial maturity is likely to remain uneven because clinical availability does not automatically translate into funded and scalable access. For manufacturers, regional expansion will increasingly require differentiated pricing, public-health partnerships and service-delivery models adapted to local testing and follow-up capacity.
Competitive Landscape Analysis
The confirmed commercial landscape of Long-Acting HIV PrEP is highly concentrated around ViiV Healthcare and Gilead Sciences, but their competitive positioning is differentiated rather than directly homogeneous. ViiV Healthcare established the earlier long-acting injectable PrEP model through cabotegravir, building its position around an intramuscular regimen with maintenance injections every two months. Gilead Sciences subsequently entered the market with lenacapavir and differentiated its offering through a novel HIV-1 capsid mechanism and twice-yearly subcutaneous dosing. As a result, competition is increasingly centered on dosing interval, route of administration, implementation convenience, clinical confidence and access rather than price alone. ViiV's earlier commercialization supports accumulated provider familiarity, whereas Gilead's six-month dosing interval creates a strong product-level differentiation point. Future competitive outcomes will depend on how effectively each company converts these pharmacological and dosing characteristics into sustained patient uptake, reimbursement coverage and integration into national and community-based HIV prevention programs.
Report Scope
LPI (LP Information)' newest research report, the “Long-Acting HIV PrEP Industry Forecast” looks at past sales and reviews total world Long-Acting HIV PrEP sales in 2025, providing a comprehensive analysis by region and market sector of projected Long-Acting HIV PrEP sales for 2026 through 2032. With Long-Acting HIV PrEP sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-Acting HIV PrEP industry.
This Insight Report provides a comprehensive analysis of the global Long-Acting HIV PrEP landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Long-Acting HIV PrEP portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-Acting HIV PrEP market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-Acting HIV PrEP and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-Acting HIV PrEP.
This report presents a comprehensive overview, market shares, and growth opportunities of Long-Acting HIV PrEP market by product type, application, key players and key regions and countries.
Market Segmentation
Segmentation by Type:
- Cabotegravir Long-Acting PrEP
- Lenacapavir Long-Acting PrEP
Segmentation by Route of Administration:
- Intramuscular Injectable PrEP
- Subcutaneous Injectable PrEP
Segmentation by Time of Administration:
- Every 2 Months
- Every 6 Months
Segmentation by Application:
- Hospitals and HIV Specialty Clinics
- Sexual Health Clinics
- Public Health PrEP Programs
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Gilead Sciences
- GSK
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Long-Acting HIV PrEP Market Size (2021-2032)
2.1.2 Long-Acting HIV PrEP Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Long-Acting HIV PrEP by Country/Region (2021, 2025 & 2032)
2.2 Long-Acting HIV PrEP Segment by Type
2.2.1 Cabotegravir Long-Acting PrEP
2.2.2 Lenacapavir Long-Acting PrEP
2.2.3 Long-Acting HIV PrEP Market Size by Type
2.2.3.1 Long-Acting HIV PrEP Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global Long-Acting HIV PrEP Market Size Market Share by Type (2021-2026)
2.3 Long-Acting HIV PrEP Segment by Route of Administration
2.3.1 Intramuscular Injectable PrEP
2.3.2 Subcutaneous Injectable PrEP
2.3.3 Long-Acting HIV PrEP Market Size by Route of Administration
2.3.3.1 Long-Acting HIV PrEP Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032)
2.3.3.2 Global Long-Acting HIV PrEP Market Size Market Share by Route of Administration (2021-2026)
2.4 Long-Acting HIV PrEP Segment by Time of Administration
2.4.1 Every 2 Months
2.4.2 Every 6 Months
2.4.3 Long-Acting HIV PrEP Market Size by Time of Administration
2.4.3.1 Long-Acting HIV PrEP Market Size CAGR by Time of Administration (2021 VS 2025 VS 2032)
2.4.3.2 Global Long-Acting HIV PrEP Market Size Market Share by Time of Administration (2021-2026)
2.5 Long-Acting HIV PrEP Segment by Application
2.5.1 Hospitals and HIV Specialty Clinics
2.5.2 Sexual Health Clinics
2.5.3 Public Health PrEP Programs
2.5.4 Long-Acting HIV PrEP Market Size by Application
2.5.4.1 Long-Acting HIV PrEP Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.4.2 Global Long-Acting HIV PrEP Market Size Market Share by Application (2021-2026)
3 LONG-ACTING HIV PREP MARKET SIZE BY PLAYER
3.1 Long-Acting HIV PrEP Market Size Market Share by Player
3.1.1 Global Long-Acting HIV PrEP Revenue by Player (2021-2026)
3.1.2 Global Long-Acting HIV PrEP Revenue Market Share by Player (2021-2026)
3.2 Global Long-Acting HIV PrEP Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 LONG-ACTING HIV PREP BY REGION
4.1 Long-Acting HIV PrEP Market Size by Region (2021-2026)
4.2 Global Long-Acting HIV PrEP Annual Revenue by Country/Region (2021-2026)
4.3 Americas Long-Acting HIV PrEP Market Size Growth (2021-2026)
4.4 APAC Long-Acting HIV PrEP Market Size Growth (2021-2026)
4.5 Europe Long-Acting HIV PrEP Market Size Growth (2021-2026)
4.6 Middle East & Africa Long-Acting HIV PrEP Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Long-Acting HIV PrEP Market Size by Country (2021-2026)
5.2 Americas Long-Acting HIV PrEP Market Size by Type (2021-2026)
5.3 Americas Long-Acting HIV PrEP Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Long-Acting HIV PrEP Market Size by Region (2021-2026)
6.2 APAC Long-Acting HIV PrEP Market Size by Type (2021-2026)
6.3 APAC Long-Acting HIV PrEP Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Long-Acting HIV PrEP Market Size by Country (2021-2026)
7.2 Europe Long-Acting HIV PrEP Market Size by Type (2021-2026)
7.3 Europe Long-Acting HIV PrEP Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Long-Acting HIV PrEP by Region (2021-2026)
8.2 Middle East & Africa Long-Acting HIV PrEP Market Size by Type (2021-2026)
8.3 Middle East & Africa Long-Acting HIV PrEP Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL LONG-ACTING HIV PREP MARKET FORECAST
10.1 Global Long-Acting HIV PrEP Forecast by Region (2027-2032)
10.1.1 Global Long-Acting HIV PrEP Forecast by Region (2027-2032)
10.1.2 Americas Long-Acting HIV PrEP Forecast
10.1.3 APAC Long-Acting HIV PrEP Forecast
10.1.4 Europe Long-Acting HIV PrEP Forecast
10.1.5 Middle East & Africa Long-Acting HIV PrEP Forecast
10.2 Americas Long-Acting HIV PrEP Forecast by Country (2027-2032)
10.2.1 United States Market Long-Acting HIV PrEP Forecast
10.2.2 Canada Market Long-Acting HIV PrEP Forecast
10.2.3 Mexico Market Long-Acting HIV PrEP Forecast
10.2.4 Brazil Market Long-Acting HIV PrEP Forecast
10.3 APAC Long-Acting HIV PrEP Forecast by Region (2027-2032)
10.3.1 China Long-Acting HIV PrEP Market Forecast
10.3.2 Japan Market Long-Acting HIV PrEP Forecast
10.3.3 Korea Market Long-Acting HIV PrEP Forecast
10.3.4 Southeast Asia Market Long-Acting HIV PrEP Forecast
10.3.5 India Market Long-Acting HIV PrEP Forecast
10.3.6 Australia Market Long-Acting HIV PrEP Forecast
10.4 Europe Long-Acting HIV PrEP Forecast by Country (2027-2032)
10.4.1 Germany Market Long-Acting HIV PrEP Forecast
10.4.2 France Market Long-Acting HIV PrEP Forecast
10.4.3 UK Market Long-Acting HIV PrEP Forecast
10.4.4 Italy Market Long-Acting HIV PrEP Forecast
10.4.5 Russia Market Long-Acting HIV PrEP Forecast
10.5 Middle East & Africa Long-Acting HIV PrEP Forecast by Region (2027-2032)
10.5.1 Egypt Market Long-Acting HIV PrEP Forecast
10.5.2 South Africa Market Long-Acting HIV PrEP Forecast
10.5.3 Israel Market Long-Acting HIV PrEP Forecast
10.5.4 Turkey Market Long-Acting HIV PrEP Forecast
10.6 Global Long-Acting HIV PrEP Forecast by Type (2027-2032)
10.7 Global Long-Acting HIV PrEP Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Long-Acting HIV PrEP Forecast
11 KEY PLAYERS ANALYSIS
11.1 Gilead Sciences
11.1.1 Gilead Sciences Company Information
11.1.2 Gilead Sciences Long-Acting HIV PrEP Product Offered
11.1.3 Gilead Sciences Long-Acting HIV PrEP Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Gilead Sciences Main Business Overview
11.1.5 Gilead Sciences Latest Developments
11.2 GSK
11.2.1 GSK Company Information
11.2.2 GSK Long-Acting HIV PrEP Product Offered
11.2.3 GSK Long-Acting HIV PrEP Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 GSK Main Business Overview
11.2.5 GSK Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Long-Acting HIV PrEP Market Size (2021-2032)
2.1.2 Long-Acting HIV PrEP Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Long-Acting HIV PrEP by Country/Region (2021, 2025 & 2032)
2.2 Long-Acting HIV PrEP Segment by Type
2.2.1 Cabotegravir Long-Acting PrEP
2.2.2 Lenacapavir Long-Acting PrEP
2.2.3 Long-Acting HIV PrEP Market Size by Type
2.2.3.1 Long-Acting HIV PrEP Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global Long-Acting HIV PrEP Market Size Market Share by Type (2021-2026)
2.3 Long-Acting HIV PrEP Segment by Route of Administration
2.3.1 Intramuscular Injectable PrEP
2.3.2 Subcutaneous Injectable PrEP
2.3.3 Long-Acting HIV PrEP Market Size by Route of Administration
2.3.3.1 Long-Acting HIV PrEP Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032)
2.3.3.2 Global Long-Acting HIV PrEP Market Size Market Share by Route of Administration (2021-2026)
2.4 Long-Acting HIV PrEP Segment by Time of Administration
2.4.1 Every 2 Months
2.4.2 Every 6 Months
2.4.3 Long-Acting HIV PrEP Market Size by Time of Administration
2.4.3.1 Long-Acting HIV PrEP Market Size CAGR by Time of Administration (2021 VS 2025 VS 2032)
2.4.3.2 Global Long-Acting HIV PrEP Market Size Market Share by Time of Administration (2021-2026)
2.5 Long-Acting HIV PrEP Segment by Application
2.5.1 Hospitals and HIV Specialty Clinics
2.5.2 Sexual Health Clinics
2.5.3 Public Health PrEP Programs
2.5.4 Long-Acting HIV PrEP Market Size by Application
2.5.4.1 Long-Acting HIV PrEP Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.4.2 Global Long-Acting HIV PrEP Market Size Market Share by Application (2021-2026)
3 LONG-ACTING HIV PREP MARKET SIZE BY PLAYER
3.1 Long-Acting HIV PrEP Market Size Market Share by Player
3.1.1 Global Long-Acting HIV PrEP Revenue by Player (2021-2026)
3.1.2 Global Long-Acting HIV PrEP Revenue Market Share by Player (2021-2026)
3.2 Global Long-Acting HIV PrEP Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 LONG-ACTING HIV PREP BY REGION
4.1 Long-Acting HIV PrEP Market Size by Region (2021-2026)
4.2 Global Long-Acting HIV PrEP Annual Revenue by Country/Region (2021-2026)
4.3 Americas Long-Acting HIV PrEP Market Size Growth (2021-2026)
4.4 APAC Long-Acting HIV PrEP Market Size Growth (2021-2026)
4.5 Europe Long-Acting HIV PrEP Market Size Growth (2021-2026)
4.6 Middle East & Africa Long-Acting HIV PrEP Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Long-Acting HIV PrEP Market Size by Country (2021-2026)
5.2 Americas Long-Acting HIV PrEP Market Size by Type (2021-2026)
5.3 Americas Long-Acting HIV PrEP Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Long-Acting HIV PrEP Market Size by Region (2021-2026)
6.2 APAC Long-Acting HIV PrEP Market Size by Type (2021-2026)
6.3 APAC Long-Acting HIV PrEP Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Long-Acting HIV PrEP Market Size by Country (2021-2026)
7.2 Europe Long-Acting HIV PrEP Market Size by Type (2021-2026)
7.3 Europe Long-Acting HIV PrEP Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Long-Acting HIV PrEP by Region (2021-2026)
8.2 Middle East & Africa Long-Acting HIV PrEP Market Size by Type (2021-2026)
8.3 Middle East & Africa Long-Acting HIV PrEP Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL LONG-ACTING HIV PREP MARKET FORECAST
10.1 Global Long-Acting HIV PrEP Forecast by Region (2027-2032)
10.1.1 Global Long-Acting HIV PrEP Forecast by Region (2027-2032)
10.1.2 Americas Long-Acting HIV PrEP Forecast
10.1.3 APAC Long-Acting HIV PrEP Forecast
10.1.4 Europe Long-Acting HIV PrEP Forecast
10.1.5 Middle East & Africa Long-Acting HIV PrEP Forecast
10.2 Americas Long-Acting HIV PrEP Forecast by Country (2027-2032)
10.2.1 United States Market Long-Acting HIV PrEP Forecast
10.2.2 Canada Market Long-Acting HIV PrEP Forecast
10.2.3 Mexico Market Long-Acting HIV PrEP Forecast
10.2.4 Brazil Market Long-Acting HIV PrEP Forecast
10.3 APAC Long-Acting HIV PrEP Forecast by Region (2027-2032)
10.3.1 China Long-Acting HIV PrEP Market Forecast
10.3.2 Japan Market Long-Acting HIV PrEP Forecast
10.3.3 Korea Market Long-Acting HIV PrEP Forecast
10.3.4 Southeast Asia Market Long-Acting HIV PrEP Forecast
10.3.5 India Market Long-Acting HIV PrEP Forecast
10.3.6 Australia Market Long-Acting HIV PrEP Forecast
10.4 Europe Long-Acting HIV PrEP Forecast by Country (2027-2032)
10.4.1 Germany Market Long-Acting HIV PrEP Forecast
10.4.2 France Market Long-Acting HIV PrEP Forecast
10.4.3 UK Market Long-Acting HIV PrEP Forecast
10.4.4 Italy Market Long-Acting HIV PrEP Forecast
10.4.5 Russia Market Long-Acting HIV PrEP Forecast
10.5 Middle East & Africa Long-Acting HIV PrEP Forecast by Region (2027-2032)
10.5.1 Egypt Market Long-Acting HIV PrEP Forecast
10.5.2 South Africa Market Long-Acting HIV PrEP Forecast
10.5.3 Israel Market Long-Acting HIV PrEP Forecast
10.5.4 Turkey Market Long-Acting HIV PrEP Forecast
10.6 Global Long-Acting HIV PrEP Forecast by Type (2027-2032)
10.7 Global Long-Acting HIV PrEP Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Long-Acting HIV PrEP Forecast
11 KEY PLAYERS ANALYSIS
11.1 Gilead Sciences
11.1.1 Gilead Sciences Company Information
11.1.2 Gilead Sciences Long-Acting HIV PrEP Product Offered
11.1.3 Gilead Sciences Long-Acting HIV PrEP Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Gilead Sciences Main Business Overview
11.1.5 Gilead Sciences Latest Developments
11.2 GSK
11.2.1 GSK Company Information
11.2.2 GSK Long-Acting HIV PrEP Product Offered
11.2.3 GSK Long-Acting HIV PrEP Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 GSK Main Business Overview
11.2.5 GSK Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Long-Acting HIV PrEP Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Long-Acting HIV PrEP Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Cabotegravir Long-Acting PrEP
Table 4. Major Players of Lenacapavir Long-Acting PrEP
Table 5. Long-Acting HIV PrEP Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Long-Acting HIV PrEP Market Size by Type (2021-2026) & ($ millions)
Table 7. Global Long-Acting HIV PrEP Market Size Market Share by Type (2021-2026)
Table 8. Major Players of Intramuscular Injectable PrEP
Table 9. Major Players of Subcutaneous Injectable PrEP
Table 10. Long-Acting HIV PrEP Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032) & ($ millions)
Table 11. Global Long-Acting HIV PrEP Market Size by Route of Administration (2021-2026) & ($ millions)
Table 12. Global Long-Acting HIV PrEP Market Size Market Share by Route of Administration (2021-2026)
Table 13. Major Players of Every 2 Months
Table 14. Major Players of Every 6 Months
Table 15. Long-Acting HIV PrEP Market Size CAGR by Time of Administration (2021 VS 2025 VS 2032) & ($ millions)
Table 16. Global Long-Acting HIV PrEP Market Size by Time of Administration (2021-2026) & ($ millions)
Table 17. Global Long-Acting HIV PrEP Market Size Market Share by Time of Administration (2021-2026)
Table 18. Long-Acting HIV PrEP Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 19. Global Long-Acting HIV PrEP Market Size by Application (2021-2026) & ($ millions)
Table 20. Global Long-Acting HIV PrEP Market Size Market Share by Application (2021-2026)
Table 21. Global Long-Acting HIV PrEP Revenue by Player (2021-2026) & ($ millions)
Table 22. Global Long-Acting HIV PrEP Revenue Market Share by Player (2021-2026)
Table 23. Long-Acting HIV PrEP Key Players Head office and Products Offered
Table 24. Long-Acting HIV PrEP Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Long-Acting HIV PrEP Market Size by Region (2021-2026) & ($ millions)
Table 28. Global Long-Acting HIV PrEP Market Size Market Share by Region (2021-2026)
Table 29. Global Long-Acting HIV PrEP Revenue by Country/Region (2021-2026) & ($ millions)
Table 30. Global Long-Acting HIV PrEP Revenue Market Share by Country/Region (2021-2026)
Table 31. Americas Long-Acting HIV PrEP Market Size by Country (2021-2026) & ($ millions)
Table 32. Americas Long-Acting HIV PrEP Market Size Market Share by Country (2021-2026)
Table 33. Americas Long-Acting HIV PrEP Market Size by Type (2021-2026) & ($ millions)
Table 34. Americas Long-Acting HIV PrEP Market Size Market Share by Type (2021-2026)
Table 35. Americas Long-Acting HIV PrEP Market Size by Application (2021-2026) & ($ millions)
Table 36. Americas Long-Acting HIV PrEP Market Size Market Share by Application (2021-2026)
Table 37. APAC Long-Acting HIV PrEP Market Size by Region (2021-2026) & ($ millions)
Table 38. APAC Long-Acting HIV PrEP Market Size Market Share by Region (2021-2026)
Table 39. APAC Long-Acting HIV PrEP Market Size by Type (2021-2026) & ($ millions)
Table 40. APAC Long-Acting HIV PrEP Market Size by Application (2021-2026) & ($ millions)
Table 41. Europe Long-Acting HIV PrEP Market Size by Country (2021-2026) & ($ millions)
Table 42. Europe Long-Acting HIV PrEP Market Size Market Share by Country (2021-2026)
Table 43. Europe Long-Acting HIV PrEP Market Size by Type (2021-2026) & ($ millions)
Table 44. Europe Long-Acting HIV PrEP Market Size by Application (2021-2026) & ($ millions)
Table 45. Middle East & Africa Long-Acting HIV PrEP Market Size by Region (2021-2026) & ($ millions)
Table 46. Middle East & Africa Long-Acting HIV PrEP Market Size by Type (2021-2026) & ($ millions)
Table 47. Middle East & Africa Long-Acting HIV PrEP Market Size by Application (2021-2026) & ($ millions)
Table 48. Key Market Drivers & Growth Opportunities of Long-Acting HIV PrEP
Table 49. Key Market Challenges & Risks of Long-Acting HIV PrEP
Table 50. Key Industry Trends of Long-Acting HIV PrEP
Table 51. Global Long-Acting HIV PrEP Market Size Forecast by Region (2027-2032) & ($ millions)
Table 52. Global Long-Acting HIV PrEP Market Size Market Share Forecast by Region (2027-2032)
Table 53. Global Long-Acting HIV PrEP Market Size Forecast by Type (2027-2032) & ($ millions)
Table 54. Global Long-Acting HIV PrEP Market Size Forecast by Application (2027-2032) & ($ millions)
Table 55. Gilead Sciences Details, Company Type, Long-Acting HIV PrEP Area Served and Its Competitors
Table 56. Gilead Sciences Long-Acting HIV PrEP Product Offered
Table 57. Gilead Sciences Long-Acting HIV PrEP Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 58. Gilead Sciences Main Business
Table 59. Gilead Sciences Latest Developments
Table 60. GSK Details, Company Type, Long-Acting HIV PrEP Area Served and Its Competitors
Table 61. GSK Long-Acting HIV PrEP Product Offered
Table 62. GSK Long-Acting HIV PrEP Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. GSK Main Business
Table 64. GSK Latest Developments
Table 1. Long-Acting HIV PrEP Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Long-Acting HIV PrEP Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Cabotegravir Long-Acting PrEP
Table 4. Major Players of Lenacapavir Long-Acting PrEP
Table 5. Long-Acting HIV PrEP Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Long-Acting HIV PrEP Market Size by Type (2021-2026) & ($ millions)
Table 7. Global Long-Acting HIV PrEP Market Size Market Share by Type (2021-2026)
Table 8. Major Players of Intramuscular Injectable PrEP
Table 9. Major Players of Subcutaneous Injectable PrEP
Table 10. Long-Acting HIV PrEP Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032) & ($ millions)
Table 11. Global Long-Acting HIV PrEP Market Size by Route of Administration (2021-2026) & ($ millions)
Table 12. Global Long-Acting HIV PrEP Market Size Market Share by Route of Administration (2021-2026)
Table 13. Major Players of Every 2 Months
Table 14. Major Players of Every 6 Months
Table 15. Long-Acting HIV PrEP Market Size CAGR by Time of Administration (2021 VS 2025 VS 2032) & ($ millions)
Table 16. Global Long-Acting HIV PrEP Market Size by Time of Administration (2021-2026) & ($ millions)
Table 17. Global Long-Acting HIV PrEP Market Size Market Share by Time of Administration (2021-2026)
Table 18. Long-Acting HIV PrEP Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 19. Global Long-Acting HIV PrEP Market Size by Application (2021-2026) & ($ millions)
Table 20. Global Long-Acting HIV PrEP Market Size Market Share by Application (2021-2026)
Table 21. Global Long-Acting HIV PrEP Revenue by Player (2021-2026) & ($ millions)
Table 22. Global Long-Acting HIV PrEP Revenue Market Share by Player (2021-2026)
Table 23. Long-Acting HIV PrEP Key Players Head office and Products Offered
Table 24. Long-Acting HIV PrEP Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Long-Acting HIV PrEP Market Size by Region (2021-2026) & ($ millions)
Table 28. Global Long-Acting HIV PrEP Market Size Market Share by Region (2021-2026)
Table 29. Global Long-Acting HIV PrEP Revenue by Country/Region (2021-2026) & ($ millions)
Table 30. Global Long-Acting HIV PrEP Revenue Market Share by Country/Region (2021-2026)
Table 31. Americas Long-Acting HIV PrEP Market Size by Country (2021-2026) & ($ millions)
Table 32. Americas Long-Acting HIV PrEP Market Size Market Share by Country (2021-2026)
Table 33. Americas Long-Acting HIV PrEP Market Size by Type (2021-2026) & ($ millions)
Table 34. Americas Long-Acting HIV PrEP Market Size Market Share by Type (2021-2026)
Table 35. Americas Long-Acting HIV PrEP Market Size by Application (2021-2026) & ($ millions)
Table 36. Americas Long-Acting HIV PrEP Market Size Market Share by Application (2021-2026)
Table 37. APAC Long-Acting HIV PrEP Market Size by Region (2021-2026) & ($ millions)
Table 38. APAC Long-Acting HIV PrEP Market Size Market Share by Region (2021-2026)
Table 39. APAC Long-Acting HIV PrEP Market Size by Type (2021-2026) & ($ millions)
Table 40. APAC Long-Acting HIV PrEP Market Size by Application (2021-2026) & ($ millions)
Table 41. Europe Long-Acting HIV PrEP Market Size by Country (2021-2026) & ($ millions)
Table 42. Europe Long-Acting HIV PrEP Market Size Market Share by Country (2021-2026)
Table 43. Europe Long-Acting HIV PrEP Market Size by Type (2021-2026) & ($ millions)
Table 44. Europe Long-Acting HIV PrEP Market Size by Application (2021-2026) & ($ millions)
Table 45. Middle East & Africa Long-Acting HIV PrEP Market Size by Region (2021-2026) & ($ millions)
Table 46. Middle East & Africa Long-Acting HIV PrEP Market Size by Type (2021-2026) & ($ millions)
Table 47. Middle East & Africa Long-Acting HIV PrEP Market Size by Application (2021-2026) & ($ millions)
Table 48. Key Market Drivers & Growth Opportunities of Long-Acting HIV PrEP
Table 49. Key Market Challenges & Risks of Long-Acting HIV PrEP
Table 50. Key Industry Trends of Long-Acting HIV PrEP
Table 51. Global Long-Acting HIV PrEP Market Size Forecast by Region (2027-2032) & ($ millions)
Table 52. Global Long-Acting HIV PrEP Market Size Market Share Forecast by Region (2027-2032)
Table 53. Global Long-Acting HIV PrEP Market Size Forecast by Type (2027-2032) & ($ millions)
Table 54. Global Long-Acting HIV PrEP Market Size Forecast by Application (2027-2032) & ($ millions)
Table 55. Gilead Sciences Details, Company Type, Long-Acting HIV PrEP Area Served and Its Competitors
Table 56. Gilead Sciences Long-Acting HIV PrEP Product Offered
Table 57. Gilead Sciences Long-Acting HIV PrEP Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 58. Gilead Sciences Main Business
Table 59. Gilead Sciences Latest Developments
Table 60. GSK Details, Company Type, Long-Acting HIV PrEP Area Served and Its Competitors
Table 61. GSK Long-Acting HIV PrEP Product Offered
Table 62. GSK Long-Acting HIV PrEP Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. GSK Main Business
Table 64. GSK Latest Developments
LIST OF FIGURES
Figure 1. Long-Acting HIV PrEP Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Long-Acting HIV PrEP Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Long-Acting HIV PrEP Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Long-Acting HIV PrEP Sales Market Share by Country/Region (2025)
Figure 8. Long-Acting HIV PrEP Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Long-Acting HIV PrEP Market Size Market Share by Type in 2025
Figure 10. Global Long-Acting HIV PrEP Market Size Market Share by Route of Administration in 2025
Figure 11. Global Long-Acting HIV PrEP Market Size Market Share by Time of Administration in 2025
Figure 12. Long-Acting HIV PrEP in Hospitals and HIV Specialty Clinics
Figure 13. Global Long-Acting HIV PrEP Market: Hospitals and HIV Specialty Clinics (2021-2026) & ($ millions)
Figure 14. Long-Acting HIV PrEP in Sexual Health Clinics
Figure 15. Global Long-Acting HIV PrEP Market: Sexual Health Clinics (2021-2026) & ($ millions)
Figure 16. Long-Acting HIV PrEP in Public Health PrEP Programs
Figure 17. Global Long-Acting HIV PrEP Market: Public Health PrEP Programs (2021-2026) & ($ millions)
Figure 18. Global Long-Acting HIV PrEP Market Size Market Share by Application in 2025
Figure 19. Global Long-Acting HIV PrEP Revenue Market Share by Player in 2025
Figure 20. Global Long-Acting HIV PrEP Market Size Market Share by Region (2021-2026)
Figure 21. Americas Long-Acting HIV PrEP Market Size 2021-2026 ($ millions)
Figure 22. APAC Long-Acting HIV PrEP Market Size 2021-2026 ($ millions)
Figure 23. Europe Long-Acting HIV PrEP Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa Long-Acting HIV PrEP Market Size 2021-2026 ($ millions)
Figure 25. Americas Long-Acting HIV PrEP Value Market Share by Country in 2025
Figure 26. United States Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC Long-Acting HIV PrEP Market Size Market Share by Region in 2025
Figure 31. APAC Long-Acting HIV PrEP Market Size Market Share by Type (2021-2026)
Figure 32. APAC Long-Acting HIV PrEP Market Size Market Share by Application (2021-2026)
Figure 33. China Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 37. India Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe Long-Acting HIV PrEP Market Size Market Share by Country in 2025
Figure 40. Europe Long-Acting HIV PrEP Market Size Market Share by Type (2021-2026)
Figure 41. Europe Long-Acting HIV PrEP Market Size Market Share by Application (2021-2026)
Figure 42. Germany Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 43. France Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 44. UK Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa Long-Acting HIV PrEP Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa Long-Acting HIV PrEP Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa Long-Acting HIV PrEP Market Size Market Share by Application (2021-2026)
Figure 50. Egypt Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 56. APAC Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 57. Europe Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 59. United States Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 60. Canada Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 61. Mexico Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 62. Brazil Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 63. China Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 64. Japan Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 65. Korea Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 67. India Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 68. Australia Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 69. Germany Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 70. France Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 71. UK Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 72. Italy Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 73. Russia Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 74. Egypt Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 75. South Africa Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 76. Israel Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 77. Turkey Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 78. Global Long-Acting HIV PrEP Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global Long-Acting HIV PrEP Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 1. Long-Acting HIV PrEP Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Long-Acting HIV PrEP Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Long-Acting HIV PrEP Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Long-Acting HIV PrEP Sales Market Share by Country/Region (2025)
Figure 8. Long-Acting HIV PrEP Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Long-Acting HIV PrEP Market Size Market Share by Type in 2025
Figure 10. Global Long-Acting HIV PrEP Market Size Market Share by Route of Administration in 2025
Figure 11. Global Long-Acting HIV PrEP Market Size Market Share by Time of Administration in 2025
Figure 12. Long-Acting HIV PrEP in Hospitals and HIV Specialty Clinics
Figure 13. Global Long-Acting HIV PrEP Market: Hospitals and HIV Specialty Clinics (2021-2026) & ($ millions)
Figure 14. Long-Acting HIV PrEP in Sexual Health Clinics
Figure 15. Global Long-Acting HIV PrEP Market: Sexual Health Clinics (2021-2026) & ($ millions)
Figure 16. Long-Acting HIV PrEP in Public Health PrEP Programs
Figure 17. Global Long-Acting HIV PrEP Market: Public Health PrEP Programs (2021-2026) & ($ millions)
Figure 18. Global Long-Acting HIV PrEP Market Size Market Share by Application in 2025
Figure 19. Global Long-Acting HIV PrEP Revenue Market Share by Player in 2025
Figure 20. Global Long-Acting HIV PrEP Market Size Market Share by Region (2021-2026)
Figure 21. Americas Long-Acting HIV PrEP Market Size 2021-2026 ($ millions)
Figure 22. APAC Long-Acting HIV PrEP Market Size 2021-2026 ($ millions)
Figure 23. Europe Long-Acting HIV PrEP Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa Long-Acting HIV PrEP Market Size 2021-2026 ($ millions)
Figure 25. Americas Long-Acting HIV PrEP Value Market Share by Country in 2025
Figure 26. United States Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC Long-Acting HIV PrEP Market Size Market Share by Region in 2025
Figure 31. APAC Long-Acting HIV PrEP Market Size Market Share by Type (2021-2026)
Figure 32. APAC Long-Acting HIV PrEP Market Size Market Share by Application (2021-2026)
Figure 33. China Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 37. India Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe Long-Acting HIV PrEP Market Size Market Share by Country in 2025
Figure 40. Europe Long-Acting HIV PrEP Market Size Market Share by Type (2021-2026)
Figure 41. Europe Long-Acting HIV PrEP Market Size Market Share by Application (2021-2026)
Figure 42. Germany Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 43. France Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 44. UK Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa Long-Acting HIV PrEP Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa Long-Acting HIV PrEP Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa Long-Acting HIV PrEP Market Size Market Share by Application (2021-2026)
Figure 50. Egypt Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries Long-Acting HIV PrEP Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 56. APAC Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 57. Europe Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 59. United States Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 60. Canada Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 61. Mexico Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 62. Brazil Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 63. China Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 64. Japan Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 65. Korea Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 67. India Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 68. Australia Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 69. Germany Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 70. France Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 71. UK Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 72. Italy Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 73. Russia Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 74. Egypt Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 75. South Africa Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 76. Israel Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 77. Turkey Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
Figure 78. Global Long-Acting HIV PrEP Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global Long-Acting HIV PrEP Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries Long-Acting HIV PrEP Market Size 2027-2032 ($ millions)
